MAPT and neurodegenerative disease: [18F]Florzolotau has been proven capable of detecting both 3R tau and 4R tau isoforms (Ono et al. 2017) and recent investigations have provided compelling evidence for the effectiveness of [18F]Florzolotau in identifying tau pathologies in different types of neurodegenerative diseases, such as AD, CBD, PDD, and PSP (Tagai et al. 2021; Li et al. 2021; Miyamoto et al. 2023; Liu et al. 2023a, b; Tang et al. 2023).